Commentary The People’s Republic of China has embarked on a major international distribution push of Sinovac and Sinopharm vaccines worldwide. Sinovac is one of China’s COVID-19 vaccines, which has now been made available to more than 45 countries, mainly in South America and Africa, but also in Singapore, Malaysia, the Philippines, Indonesia, and Turkey. Sinopharm is a state-owned company, the vaccine of which has been either donated to or purchased by various countries. According to reports, the alleged success rate of Sinovac varies wildly, with Brazil claiming a success rate of barely 50.4 percent, while Turkey reported a 91.25 percent rate, and Indonesia 65.3 percent. Disregarding the effectiveness of these vaccines, China’s contribution to the world vaccination effort has undoubtedly changed the global perception of China. From a country that negligently or deliberately concealed the existence of the virus (thereby allowing its spread) to a country that is part of …